February 11, 2022:

Big Ten Cancer Research Consortium investigators presented a trial in progress abstract at the 2021 San Antonio Breast Cancer Symposium. The abstract titled, A Phase II Study of Pembrolizumab plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients, was presented by Nancy Chan, MD of Rutgers Cancer Institute of New Jersey.

The primary goal of the single arm, phase II study BTCRC-BRE16-042 is to evaluate the overall response rate of pembrolizumab plus fulvestrant in patients with hormone receptor positive, HER2 negative advanced/metastatic breast cancer. The secondary objective of the trial is to describe the toxicity profile of pembrolizumab plus fulvestrant in patients with hormone receptor positive, HER2 negative advanced/metastatic breast cancer, to estimate the progression free survival of pembrolizumab plus fulvestrant in patients with hormone receptor positive, HER2 negative advanced/metastatic breast cancer, to estimate the durable response rate of pembrolizumab plus fulvestrant in patients with hormone receptor positive, HER2 negative advanced/metastatic breast cancer and to estimate the overall survival of pembrolizumab plus fulvestrant in patients with hormone receptor positive, HER2 negative advanced/metastatic breast cancer.

Participating institutions include Michigan State University, Rutgers Cancer Institute of New Jersey, University of Nebraska Medical Center and the University of Wisconsin.

Authors include Chan N, Moore D, Tandra P, Rana J, Omene C, George M, Krishnamurthy J, Desai S, Patel N, Wang Y, Bicomong M, Tan X-w, Hirshfield K, Ganesan S, Toppmeyer D.

About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities. The goal of the Big Ten Cancer Research Consortium is to create a unique team-research culture to drive science rapidly from ideas to new approaches to cancer treatment. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow with the unified goal of improving the lives of all patients with cancer.

About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 14 Big Ten institutions will provide over $200 million in direct financial support to more than 9,800 students for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women, including the addition of men’s ice hockey and men’s and women’s lacrosse since 2013. For more information, visit www.bigten.org